We assessed the current resistance rates of Haemophilus influenzae against b-lactams and other agents in Europe and compared the results with those of our previously performed surveillance study.
Introduction
Haemophilus influenzae is a major respiratory tract pathogen, causing acute exacerbations of chronic bronchitis, acute sinusitis and community-acquired pneumonia. Resistance of H. influenzae to b-lactam antibiotics is generally conferred by either the presence of b-lactamase (BL) or mutations in the transpeptidase domain of the penicillin binding protein (PBP) resulting in a lowered affinity for b-lactam antibiotics. 1 To date, BL production is regarded as the most common resistance mechanism among this species. In the early 1980s the first BL-negative, ampicillinresistant (BLNAR) isolates were reported. In Europe the emergence of BLNAR strains has been demonstrated in many countries ranging from 2% to 20% 2 and a percentage up to 40% has been reported in Japan. 3 Recently, a decreasing number of BL-producing H. influenzae isolates has been noted in the United States. 4 We aimed to study the current resistance rates of European H. influenzae isolates against b-lactams and other oral agents used for the treatment of respiratory tract infections and to assess the epidemiology of amoxicillin resistance in Europe over the past 7 years by comparing the results with data obtained from our previous surveillance study.
Materials and methods

Isolates
A total of 578 H. influenzae isolates were tested, prospectively collected between October 2004 and April 2005 from patients with respiratory tract infections in various university hospitals in Austria, France, Germany, Ireland, Italy, The Netherlands, Poland, Portugal, Spain, Turkey and the UK. Only one isolate per patient was included. All strains were re-identified at the Eijkman-Winkler Institute by colony morphology on chocolate agar, X and V factor requirements and haemolysis on horse blood agar. BL production was tested by the nitrocefin test (Oxoid, Basingtoke, UK). 
Susceptibility testing
The antimicrobial agents tested are listed in Table 1 . Microtitre plates containing freeze-dried serial dilutions of the antibiotics were prepared by Trek Diagnostics (East Grinstead, West Sussex, UK). MICs were determined by a microdilution method according to CLSI guidelines. H. influenzae ATCC 49247 and ATCC 49766 were used for quality control. BL-negative strains that were nonsusceptible to amoxicillin (MIC of 2 mg/L) were categorized as BLNAR. BLNAR strains were further subdivided into high-BLNAR (amoxicillin MIC 4 mg/L) and intermediate-BLNAR (amoxicillin MIC 2 mg/L). 2 
PCR and DNA sequencing
Mutations relevant for b-lactam antibiotic resistance in H. influenzae are present in the transpeptidase domain of PBP3B between amino acids 320 and 540. 5, 6 This domain was PCR amplified with the primers F1, 5 0 -TAA TGC GTA ACC GTG CAA TTA C, and F2, 5 0 -ACC ACT AAT GCA TTA CGA GGA TC. 6 The purified amplification products were sequenced using four primers. Besides primers F1 and F2 described above, the primers PBP3.seqexf, 5
0 -CTG GGC AGA TAT TGA GCG TG, and PBP3.seqexr, 5
0 -CAC GCT CAA TAT CTG CCC AG, were used to sequence the products obtained with primers F1 and F2. Mutations were determined by comparing the sequence data with the PBP3B DNA sequence with GenBank accession no. L42023.
Results and discussion
Of the 578 strains tested 95 (16.4%) were non-susceptible to amoxicillin (Table 1 ). In 44 strains (7.6%) resistance was due to BL production, whereas 51 (8.8%) showed the BLNAR phenotype, comprising 15 (2.6%) high-BLNAR and 36 (6.2%) intermediate-BLNAR strains. None of the BL-positive strains was resistant to co-amoxiclav. Levofloxacin, moxifloxacin (MIC 90 s 0.03 mg/L) and cefixime (MIC 90 0.06 mg/L) were the most active agents tested, exhibiting comparably high activities against BL-producing and BLNAR isolates. All 578 strains were susceptible to these agents. Compared with the other cephalosporins tested, cefixime was 32 times more active than cefuroxime and 128 times more active than cefaclor. The in vitro activity of telithromycin was comparable to that of azithromycin (MIC 50/90 1/2 mg/L) and these two agents were 8 times more active than clarithromycin (MIC 50/90 8/16 mg/L). Apart from amoxicillin, reduced susceptibility rates were observed for cefaclor, cefuroxime and clarithromycin, being most pronounced with BLNAR strains (76.5%, 86.3% and 80.4%, respectively). However, according to the CLSI guidelines BLNAR strains should be considered resistant to agents such as co-amoxiclav, cefaclor and cefuroxime despite in vitro susceptibility. In addition to clarithromycin, a small percentage of the strains was non-susceptible to telithromycin and azithromycin.
Resistance against these three macrolides may be due to active efflux of the drugs, in combination with mutations in the 23S rRNA and/or ribosomal proteins. 7 Considerable variation in amoxicillin resistance was noticed among strains from different European countries. The percentage of BL-positive strains ranged from 0% to 17.6%, whereas the emergence of the BLNAR phenotype of H. influenzae was demonstrated in most of the countries with a percentage ranging from 1.5% to 33.9% (Table 2) .
Compared with 1997/98 and 2002/03, the overall percentages of strains that were non-susceptible to amoxicillin decreased from 19.8% and 23.3%, respectively, to 16.4% in 2004/05 (Table 2 , P = 0.005, Pearson c 2 , SPSS 12.1). The overall percentage of BL-producing strains decreased from 11.0% and 13.7% to 7.6%, respectively (P = 0.001), whereas the overall percentage of BLNARs remained stable (8.8% and 9.6% versus 8.8%; high-BLNAR 2.8% and 3.1% versus 2.6%). Taking All 51 BLNARs and 14 amoxicillin-susceptible isolates (MICs 0.12-1 mg/L) were selected for DNA sequencing of the penicillin binding protein PBP3B. The amino acid substitutions in PBP3B deduced for these isolates are listed in Table 3 . Based on amino acid substitutions at position 526 (Asn!Lys) and 517 (Arg!His), BLNARs were subdivided into group I and group II, respectively, according to Ubukata et al. 6 A total of 86.3% belonged to group I (compared with 87.5% in 2002/2003), whereas 2.0% belonged to group II (compared with 4.2% in 2002/2003). The predominance of group I is in agreement with a recent study in the USA. 4 Except for the mutations at positions 499 (Asn!Ser) and 511 (Val!Ala), all mutations have been observed in our previous study 2 and French BLNAR strains as well. 5 However, only a subset of these mutations may be actually associated with ampicillin resistance: compared with the susceptible control isolates, BLNARs showed more than 2-fold higher mutation rates at position 377 (susceptible 7.1% versus BLNAR 21.6%, P = 0.3, Fisher's Exact Test, SPSS 12.1), position 2 490 (7.1%, 23.5%, P = 0.3), 502 (28.6%, 70.6%, P < 0.01) and 526 (21.4%, 86.3%, P < 0.001). Thus, in addition to several previously identified mutations associated with amoxicillin resistance, 5, 6, 8, 9 the significant higher mutation rate at position 502 in BLNAR strains suggests that this mutation may also contribute to amoxicillin resistance. For the group I mutation at position 526, there was a positive correlation between amoxicillin resistance levels and percentage of isolates carrying this mutation (r = 0.77, n = 6, Pearson regression analysis). In contrast to Japanese BLNAR strains, 8, 10 we neither observed additional Ser 385 and Leu 389 mutations in European BLNARs nor an enhanced number of PBP3 mutations in addition to group I and II mutations in high-BLNARs compared with intermediateBLNARs. Our results suggest that the group I mutation itself may already be associated with high-BLNARs, as the percentage of isolates carrying a mutation at this position increased with the resistance of these isolates against amoxicillin.
Although BLNAR strains were highly variable in PBP3 mutations, certain mutation profiles were country specific. The 350 (Asp!Asn), 502 (Ala!Thr) and 526 (Asn!Lys) mutation combination was unique and predominant among Spanish hospitals. This mutation profile was also uniquely observed in these hospitals in our previous study. This suggests that clonal spread of BLNAR strains may occur locally. This finding warrants further investigation by using other molecular typing methods.
In conclusion, notwithstanding large inter-regional differences, the overall resistance of H. influenzae to amoxicillin seems to decline in Europe due to a decreasing number of BL-producing strains, whereas the overall number of BLNAR strains remained relatively constant. PBP sequencing suggests the presence of several mutations associated with resistance and clonal spread of BLNAR strains. Cefixime, levofloxacin and moxifloxacin retained their excellent activity against both BL-producing and BLNAR strains of H. influenzae and thus remain useful treatment options for respiratory tract infection also in areas with persisting resistance problems.
